Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1 - PubMed
Multicenter Study
. 2008 Oct;6(10):1663-70.
doi: 10.1111/j.1538-7836.2008.03116.x. Epub 2008 Aug 1.
Affiliations
- PMID: 18680536
- DOI: 10.1111/j.1538-7836.2008.03116.x
Free article
Multicenter Study
Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1
D J Harrington et al. J Thromb Haemost. 2008 Oct.
Free article
Abstract
Background: Vitamin K epoxide reductase subunit 1 (VKORC1) is the molecular target of coumarin anticoagulants and mutations in VKORC1 have been identified previously in individuals who required high warfarin doses.
Objective: Detailed characterization of the relationship between variation in VKORC1 and the warfarin resistance phenotype.
Patients and methods: Serum warfarin concentration and coagulation parameters were determined in 289 subjects who required warfarin doses >20 mg day(-1). The VKORC1 sequence was studied in selected study subjects.
Results: Twenty-eight out of 289 (10%) subjects had serum warfarin >2.3 mg L(-1) during stable therapeutic anticoagulation indicating pharmacodynamic warfarin resistance. Detailed analysis of 15 subjects from this group showed that eight out of 15 (53%) had nucleotide substitutions in VKORC1 predictive of p.V66M, p.L128R, p.V54L or p.D36Y. VKORC1 was normal in the remaining seven out of 15 (47%) subjects and in nine out of nine (100%) subjects with high warfarin dose requirement not caused by pharmacodynamic resistance. At referral, subjects with VKORC1 mutations received a median warfarin dose of 32 mg day(-1) (range 22-55) and had a median serum warfarin concentration of 4.6 mg L(-1) (range 2.6-9.0). VKORC1 substitutions were associated with a requirement for high warfarin doses but not with adverse clinical events. Family members with VKORC1 nucleotide substitutions and not receiving warfarin had undetectable PIVKA-II and K(1) epoxide (K(1)O).
Conclusions: Nucleotide variations in VKORC1 are a common cause of pharmacodynamic warfarin resistance but are not associated with adverse outcome during anticoagulation. Mutations associated with warfarin resistance do not cause a discernible defect in VKORC1 reductase function.
Similar articles
-
Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD. Harrington DJ, et al. Thromb Haemost. 2005 Jan;93(1):23-6. doi: 10.1160/TH04-08-0540. Thromb Haemost. 2005. PMID: 15630486
-
Scott SA, Edelmann L, Kornreich R, Desnick RJ. Scott SA, et al. Am J Hum Genet. 2008 Feb;82(2):495-500. doi: 10.1016/j.ajhg.2007.10.002. Epub 2008 Jan 17. Am J Hum Genet. 2008. PMID: 18252229 Free PMC article.
-
Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M, Hasegawa A, Yamamoto K, Horiuchi R. Obayashi K, et al. Clin Pharmacol Ther. 2006 Aug;80(2):169-78. doi: 10.1016/j.clpt.2006.04.010. Clin Pharmacol Ther. 2006. PMID: 16890578
-
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T, Miyata T. Yin T, et al. Thromb Res. 2007;120(1):1-10. doi: 10.1016/j.thromres.2006.10.021. Epub 2006 Dec 11. Thromb Res. 2007. PMID: 17161452 Review.
-
VKORC1: molecular target of coumarins.
Oldenburg J, Watzka M, Rost S, Müller CR. Oldenburg J, et al. J Thromb Haemost. 2007 Jul;5 Suppl 1:1-6. doi: 10.1111/j.1538-7836.2007.02549.x. J Thromb Haemost. 2007. PMID: 17635701 Review.
Cited by
-
Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.
Fung E, Patsopoulos NA, Belknap SM, O'Rourke DJ, Robb JF, Anderson JL, Shworak NW, Moore JH. Fung E, et al. Semin Thromb Hemost. 2012 Nov;38(8):893-904. doi: 10.1055/s-0032-1328891. Epub 2012 Oct 6. Semin Thromb Hemost. 2012. PMID: 23041981 Free PMC article. Review.
-
Novel associations of VKORC1 variants with higher acenocoumarol requirements.
Anton AI, Cerezo-Manchado JJ, Padilla J, Perez-Andreu V, Corral J, Vicente V, Roldan V, Gonzalez-Conejero R. Anton AI, et al. PLoS One. 2013 May 17;8(5):e64469. doi: 10.1371/journal.pone.0064469. Print 2013. PLoS One. 2013. PMID: 23691226 Free PMC article.
-
Pratt VM, Cavallari LH, Del Tredici AL, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, Whirl-Carrillo M, Weck KE. Pratt VM, et al. J Mol Diagn. 2020 Jul;22(7):847-859. doi: 10.1016/j.jmoldx.2020.04.204. Epub 2020 May 4. J Mol Diagn. 2020. PMID: 32380173 Free PMC article.
-
VKORC1 polymorphisms and complete resistance to vitamin K antagonists: About two cases.
Benyamna I, El Fissi H, Bouzid F, El Mousadik A, Alif N. Benyamna I, et al. Biomedicine (Taipei). 2024 Mar 1;14(1):60-63. doi: 10.37796/2211-8039.1434. eCollection 2024. Biomedicine (Taipei). 2024. PMID: 38533299 Free PMC article.
-
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.
Lubitz SA, Scott SA, Rothlauf EB, Agarwal A, Peter I, Doheny D, Van Der Zee S, Jaremko M, Yoo C, Desnick RJ, Halperin JL. Lubitz SA, et al. J Thromb Haemost. 2010 May;8(5):1018-26. doi: 10.1111/j.1538-7836.2010.03792.x. Epub 2010 Feb 2. J Thromb Haemost. 2010. PMID: 20128861 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical